Hepatitis :: Abbott, Enanta to Develop and Commercialize HCV Protease Inhibitors

Abbott and Enanta Pharmaceuticals announced today that the companies have signed a worldwide agreement to develop and commercialize hepatitis C virus (HCV) NS3 and NS3/4A protease inhibitors. Enanta has discovered several HCV protease inhibitors that have demonstrated attractive efficacy and pharmacokinetic profiles in pre-clinical studies.

Nutrition :: Cognis to launch Omevital, omega-3 fatty acids at HiE

Cognis will unveil its new range of high quality omega-3 fish oil products at this year?s Health Ingredients Europe event in Frankfurt. Under the brand name Omevital?, and available in ethyl ester and triglyceride forms, the new range of marine-origin oils delivers products of outstanding quality and purity, ultra-refined through state-of-the-art manufacturing processes, in accordance with Pharma GMP standards.

Fertility :: The advent of international ‘mail-order’ egg donation

The rising demand and increasing scarcity of donor oocytes in developed countries have led to some fertility clinics sourcing oocyte donors from abroad, particularly from poorer countries, in what is referred to as ‘transnational’ or ‘international’ oocyte donation. In a further new ‘twist’ to this scheme, frozen sperm of the recipient’s male partner is exported abroad through courier mail and is used to fertilise donor oocytes in a foreign clinic to produce embryos, which are then cryopreserved and imported back by mail for transfer to the woman.

Hepatitis :: Roche and InterMune’s ITMN-191 HCV protease inhibitor for hepatitis c

Roche and InterMune Inc. announced that the companies have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from InterMune?s Hepatitis C (HCV) protease inhibitor program. The agreement includes InterMune?s lead candidate compound ITMN-191, expected to enter clinical trials before the end of the year. The companies will also collaborate on a research program to identify, develop and commercialize novel second-generation HCV protease inhibitors.